FDA approves Watson's generic version of Alzheimer's treatment

CORONA, Calif. The Food and Drug Administration has approved Watson Pharmaceuticals' generic version of Razadyne ER capsules, Watson announced on Tuesday, Dec. 16.

The extended-release capsules, known generically as galantamine hydrobromide, are used for treating Alzheimer's disease. Watson will market them in 8 mg, 16 mg and 24 mg strengths.

The branded version of the drug, made by Johnson & Johnson, had sales of $112 million for the 12 months ending in September, according to IMS Health data.